

# Characterization of human and microbial genetic components in normal colon tissue, colorectal adenomas, saliva and fecal samples

Published: 20-10-2016

Last updated: 16-04-2024

The primary objective of this study is the simultaneous characterization of human and microbiota genomic and transcriptomic components in healthy and adenoma mucosal samples as well as stool and saliva. In addition, microbiome shifts from normal...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Malignant and unspecified neoplasms gastrointestinal NEC
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON43246

### Source

ToetsingOnline

### Brief title

nvt

### Condition

- Malignant and unspecified neoplasms gastrointestinal NEC

### Synonym

Colonic polyps, microbiome

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Academisch Medisch Centrum

**Source(s) of monetary or material Support:** Janssen-Cilag,Janssen-Cilag/Janssen Prevention Center

## Intervention

**Keyword:** Colorectal adenoma, Microbiome

## Outcome measures

### Primary outcome

The primary study endpoint is the composition and abundance of microbiota genomic and transcriptomic components in healthy and adenoma mucosal samples as well as stool and saliva.

### Secondary outcome

The following secondary study parameters are designed to further compare the microbiome in normal and diseased tissues and matching stool and saliva and determine differences from patients with and without adenomas.

- Shifts in microbiome composition and abundance from normal mucosal to adenoma and its correlation with luminal and oral bacteria.
- Characterization of mechanisms through which microbiota cause or contribute to oncogenesis.
- Characterization of molecular sub-classification of polyps and its comparison to colon tumors.
- Identification of the presences of inflammation in the adenomas and its potential link with microbiome composition and abundance.
- Differences in transcriptomics and metatranscriptomics (gene expression) of normal mucosa and adenomatous tissue.
- Characterize differences in composition and abundance of oral microbiota in

patients with and without adenomas by taking saliva samples of three different oral mucosa locations.-

## Study description

### Background summary

Due to human the complexity of human gut microbiota and its implication in other gastrointestinal disorders, a potential pathogenic role for bacteria in CRC has been proposed for a long time, and more recently associations between bacteria and premalignant polyp development have also been found. Despite the advances made in this emerging field, most of the research conducted until now has studied human intestinal microflora from fecal samples. Interestingly, little is known about the potential correlation of gut microbiota with specific polyp and tumor host molecular features.

### Study objective

The primary objective of this study is the simultaneous characterization of human and microbiota genomic and transcriptomic components in healthy and adenoma mucosal samples as well as stool and saliva. In addition, microbiome shifts from normal mucosa to polyp to adenocarcinoma and its correlation with luminal and oral bacteria, mechanisms through which microbiota cause or contribute to oncogenesis, molecular sub-classification of polyps, inflammation in polyps and its potential link with the microbiome will be further investigated. This study also aims to develop tools to analyse complex microbiome structures.

### Study design

Cross-sectional study consisting of prospective tissue sampling of healthy colorectal biopsies, biopsies from adenomatous tissue and matched saliva and stool samples.

### Study burden and risks

Prior to the colonoscopy three saliva samples and two fecal samples will be obtained from the participating patients. No additional risks are associated with the retrieval of these samples. During the colonoscopy additional biopsies will be taken from healthy colorectal tissue, and after polypectomy additional biopsies will be taken from the luminal side of the resected adenoma, and the risks associated with these biopsies are a minimal bleeding risk.

## Contacts

### Public

Academisch Medisch Centrum

Meibergdreef 9  
Amsterdam 1105AZ  
NL

### Scientific

Academisch Medisch Centrum

Meibergdreef 9  
Amsterdam 1105AZ  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

- \* Scheduled for a regular colonoscopy
- \* Aged 18 years or above
- \* Colonoscopy scheduled for one of the following indications:
  - o Positive FOBT (Fecal Occult Blood Test) outside of the national screening program for colorectal cancer
  - o Follow up after polypectomy or colorectal cancer
  - o Rectal blood loss or anemia
  - o Abdominal pain
  - o Familial history of colon cancer or adenoma
  - o Abnormal radiologic imaging of the colon such as barium enema or CT colonography

- o Change in bowel habits
- \* Signed informed consent

## Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

- \* Previous surgical bowel resection, except from appendectomy
- \* Known or suspicion of inflammatory bowel disease.

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Basic science

### Recruitment

NL  
Recruitment status: Recruitment stopped

Start date (anticipated): 12-12-2016

Enrollment: 600

Type: Actual

## Ethics review

Approved WMO

Date: 20-10-2016

Application type: First submission

Review commission: METC Amsterdam UMC

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
CCMO	NL57805.018.16